R
Exchange
—
Entity type
operating
Fiscal year end
Dec 31
Headquarters
DE
Recent Filings
- 8-K494.3 KBRegulus Therapeutics Inc.Jun 25, 9:12 AM ET·0001104659-25-062408
- 10-Q5.5 MBRegulus Therapeutics Inc.May 8, 4:38 PM ET·0001628280-25-023872
- 8-K202.5 KBRegulus Therapeutics Inc.May 8, 4:15 PM ET·0001193125-25-115978
- 10-K/A894.2 KBRegulus Therapeutics Inc.Apr 30, 4:05 PM ET·0001193125-25-107128
- 8-K1.1 MBRegulus Therapeutics Inc.Apr 30, 8:27 AM ET·0001193125-25-105845
- 8-K1.5 MBRegulus Therapeutics Inc.Mar 27, 7:15 AM ET·0001193125-25-064685
- 10-K8.3 MBRegulus Therapeutics Inc.Mar 13, 4:30 PM ET·0001628280-25-012627
- 8-K201.9 KBRegulus Therapeutics Inc.Mar 13, 4:15 PM ET·0001193125-25-053925
- 8-K198.3 KBRegulus Therapeutics Inc.Mar 4, 4:01 PM ET·0001193125-25-045567
- SC 13G/A77.3 KBRegulus Therapeutics Inc.Nov 14, 5:46 PM ET·0001104659-24-119293
Insiders
10- Aker Christopher RaySr. VP & General Counsel
- ALNYLAM PHARMACEUTICALS, INC.10% Owner
- ASTRAZENECA AB10% Owner
- ASTRAZENECA PLC10% Owner
- BALTIMORE DAVIDDirector
- BARRIS PETER J10% Owner
- BASKETT FOREST10% Owner
- Behbahani Ali10% Owner
- BIOTECHNOLOGY VALUE FUND L PSee Explanation of Responses
- Biotechnology Value Trading Fund OS LPSee Explanation of Responses
Tickers
No tickers on record
Addresses
business
4224 CAMPUS POINT COURT SUITE 210
SAN DIEGO, CA, 92121
mailing
4224 CAMPUS POINT COURT SUITE 210
SAN DIEGO, CA, 92121